A Fort Lauderdale medical diagnostics technology company is expanding its European footprint after receiving an important approval from the European Union.
Vigilant Biosciences said Monday it had received a so-called CE Mark for its oral cancer diagnostics test, which is also used in detecting signs of neck and head tumors.
The approval allows Vigilant Biosciences to market the product in the 28 countries of the European Union, as well as Norway, Iceland, Liechtenstein and Switzerland.
The test, which Vigilant calls “the first and only test to detect a tumor-initiating stem cell biomarker for head and neck cancer,” works by measuring levels of cancer-specific proteins in an oral rinse.
Matthew H.J. Kim, the company’s founder and CEO, called it “a major milestone for our company, as it enables sales of the product in the EU, and also serves as a gateway for other regions of the world.”
“With numerous distribution agreements in place and an aggressive marketing strategy, we are looking forward to making an impact on the high rate of late-stage oral cancers diagnosed globally,” he added.